Apnea

Cellular M2M Module Market size to grow by USD 3.04 billion between 2022 - 2027| Market is driven by Use of M2M technology for remote patient monitoring- Technavio

Retrieved on: 
Thursday, December 14, 2023

The potential growth difference for the cellular m2m module market between 2022 and 2027 is USD 3.04 billion.

Key Points: 
  • The potential growth difference for the cellular m2m module market between 2022 and 2027 is USD 3.04 billion.
  • The expansion of the Cellular Machine-to-Machine (M2M) Module Market is significantly driven by the adoption of M2M technology for remote patient monitoring, notably within the healthcare sector.
  • Request Sample Report
    In the Cellular Machine-to-Machine (M2M) Module Market, growing concerns regarding privacy and security present a significant challenge.
  • Cellular IoT Market : The cellular IoT market size is estimated to grow at a CAGR of 23% between 2022 and 2027.

Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77

Retrieved on: 
Tuesday, December 5, 2023

The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.

Key Points: 
  • The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.
  • In collaboration with Taiwan's major medical centers and teaching hospitals, Heroic Faith has collected over 1.6 million entries of breathing sound data for AI training.
  • Heroic Faith's new General Manager, Yuan-Ren Cheng, has recently updated the company's motto from 'Saving Lives Through Innovation' to 'Saving Lives Through Communication.'
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/saving-lives-through-communicat...
    SOURCE Heroic Faith Medical Science, Inc.

Garmin's new Descent Mk3 series dive computers have 200-meter dive ratings, bright AMOLED displays and options with a built-in flashlight

Retrieved on: 
Tuesday, November 14, 2023

OLATHE, Kan., Nov. 14, 2023 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the Descent™ Mk3 series watch-style dive computers and Descent T2 transceiver with enhanced SubWave™ sonar technology that – through a soon-to-be-released software update – will add diver-to-diver messaging and Diver Assistance1 to tank pressure monitoring. Purpose-built with a dive-first approach to design, the Descent Mk3 series comes in two sizes – 43mm and 51mm – with air integration options on both and feature a vibrant touchscreen AMOLED display, a 200-meter dive-rated case with metal leakproof buttons that are fully operational at that depth, and up to 48 hours of battery life in dive mode2. The 51mm Descent Mk3i also comes with a built-in LED flashlight for greater visibility in low-light conditions—even underwater. With tools like multiple dive modes, DiveView™ maps and dive readiness score, plus Garmin's suite of health, fitness and connected features, the Descent Mk3 series helps divers make the most of their adventures above and below the surface.

Key Points: 
  • "From recreational to technical and every dive in between, the Descent Mk3 series and Descent T2 transceiver add innovative new features to help you explore deeper waters.
  • This, coupled with air integration, DiveView maps and dive readiness tools help make these premium dive computers an essential part of your dive kit."
  • –Dan Bartel, Garmin Vice President of Global Consumer Sales
    New advancements on the Descent Mk3 series make it possible to dive with greater peace of mind.
  • When using a Descent Mk3i dive computer and Descent T2 transceiver, divers will be able to send out an assistance alert to other connected divers.

Garmin unveils the Descent G1 Solar - Ocean Edition dive computer, its first-ever product made with recycled ocean-bound plastics

Retrieved on: 
Tuesday, November 14, 2023

OLATHE, Kan., Nov. 14, 2023 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the Descent™ G1 Solar – Ocean Edition, a rugged watch-style dive computer with features for both underwater and topside adventures. Designed with environmental responsibility in mind, 100 percent of the plastic used to make the watch's housing, bezel and buttons come from recycled ocean-bound plastics. In addition to its eco-friendly construction, Descent G1 Solar – Ocean Edition features a solar charging lens that lets divers explore longer with up to 25 hours of battery life in dive mode and up to 124 days in smartwatch mode when solar charging1. Eliminating the need for a separate dive computer and smartwatch, the Ocean Edition includes Garmin's popular dive features to help users make the most of their diving experience – plus multisport and smart features for an active lifestyle out of the water.

Key Points: 
  • OLATHE, Kan., Nov. 14, 2023 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the Descent™ G1 Solar – Ocean Edition , a rugged watch-style dive computer with features for both underwater and topside adventures.
  • With the Descent G1 Solar – Ocean Edition, we're taking materials that were once at risk of harming the ocean habitat and turning them into parts to help create an eco-friendly dive computer that's made to explore it."
  • –Dan Bartel, Garmin Vice President of Global Consumer Sales
    The idea for the Descent G1 Solar – Ocean Edition started as a brainstorming session between Garmin associates.
  • The Descent G1 Solar – Ocean Edition features a 45mm reinforced polymer case, scratch-resistant sapphire lens and an easy-to-read monochrome display.

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Retrieved on: 
Friday, October 13, 2023

Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.
  • Enabled by the multi-wavelength Masimo rainbow® Pulse CO-Oximetry platform, ORi is designed for use in conjunction with oxygen saturation (SpO2) to provide increased resolution of changes in oxygenation under supplemental oxygen.
  • View the full release here: https://www.businesswire.com/news/home/20231013679815/en/
    Without ORi, there is no noninvasive way to monitor oxygenation under supplemental oxygen to manage hyperoxia, or higher than normal oxygenation of arterial blood.
  • By convention, SpO2 is limited to an upper limit of 100%, but oxygenation can rise into hyperoxia when supplemental oxygen is administered.

Nitazenes: synthetic opioids more deadly than fentanyl are starting to turn up in overdose cases

Retrieved on: 
Monday, September 25, 2023

Now, a less well-known class of synthetic opioids called nitazenes is starting to crop up in overdose cases, on both sides of the Atlantic.

Key Points: 
  • Now, a less well-known class of synthetic opioids called nitazenes is starting to crop up in overdose cases, on both sides of the Atlantic.
  • Some drugs in the nitazene class are 100 times more potent than morphine – so about as potent as fentanyl.
  • It appears that chemists in clandestine labs have pored over old research papers looking for new synthetic opioids to make and stumbled across this class of deadly drugs.
  • One must assume, therefore, that some nitazenes may have the potential to be more deadly than fentanyl and heroin.

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

Retrieved on: 
Wednesday, June 28, 2023

In addition to daytime sleepiness, OSA is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.

Key Points: 
  • In addition to daytime sleepiness, OSA is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.
  • Patients with untreated OSA are 23 times more likely to suffer a heart attack and four times more likely to have a stroke.
  • It is estimated that more than one billion people worldwide and over 74 million people in North America suffer from OSA.
  • “Inaction among snorers, despite strong awareness that snoring is linked with OSA and comorbidities, is one of the novel and alarming findings from this survey.

Garmin announces its title sponsorship of the world-renowned freediving event: Vertical Blue 2023 By Garmin

Retrieved on: 
Tuesday, June 27, 2023

OLATHE, Kan., June 27, 2023 /PRNewswire/ -- Garmin (NYSE: GRMN) today announces its inaugural title sponsorship of the Vertical Blue freediving competition. This collaboration establishes Garmin as the official sponsor of one of the world's premier freediving extravaganzas. The Vertical Blue 2023 by Garmin will take place from July 20 to July 30 at Dean's Blue Hole in the Bahamas, offering a deep diving challenge for freediving enthusiasts.

Key Points: 
  • Introducing the Vertical Blue 2023 by Garmin: A Celebration of the Depths
    OLATHE, Kan., June 27, 2023 /PRNewswire/ -- Garmin (NYSE: GRMN) today announces its inaugural title sponsorship of the Vertical Blue freediving competition.
  • The Vertical Blue 2023 by Garmin will take place from July 20 to July 30 at Dean's Blue Hole in the Bahamas, offering a deep diving challenge for freediving enthusiasts.
  • Regarded as the "Wimbledon of Freediving" by The New York Times, the Vertical Blue event draws the crème de la crème of freediving athletes from around the globe.
  • Garmin's commitment to the 2023 Vertical Blue event contributes to the success of athletes and the development of this exhilarating sport.

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Retrieved on: 
Thursday, June 1, 2023

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023.

Key Points: 
  • NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023.
  • The presentations include new data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), demonstrating sustained improvement with Sunosi on measures of cognition across 8-hours with once daily dosing.
  • Additional new data and analyses include real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
  • “Cognitive impairment is a substantial burden to many patients with EDS and OSA.

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Tuesday, May 30, 2023

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami. The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD). The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).

Key Points: 
  • NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami.
  • The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD).
  • The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).
  • “MDD is the leading cause of disability worldwide and improvement in functioning is critically important to people with MDD.